Nat Commun: Genomic research may reveal potential combinatorial therapies

Breast cancer is the leading cause of cancer deaths in women worldwide.

Researcher Jean-Jacques Lebrun said that there are currently no targeted therapies for triple-negative breast cancer.

First of all, in the first part of the study, the researchers identified 150 new genes, which can either induce tumor formation (carcinogenic) or inhibit tumor formation (tumor suppressor).

Then the researchers found that in triple-negative breast cancer, the oncogenic pathway mTOR is activated, while another tumor suppressor pathway called Hippo is inhibited, which may help explain why these tumors are so aggressive and lethal.

The researchers then analyzed existing drugs that can target these pathways, and conducted in vivo and in vitro experiments, and found two effective drugs: Torin1 and verteporfin; Torin1 is a kind of blocking The second-generation drug with the same pathway of mTOR signal; Torin1 is a drug commonly used to treat retinal ophthalmopathy, which can mimic the Hipp pathway

The researchers’ findings exceeded their expectations.

The researchers said that giant pinocytosis is a natural mechanism.

The research results in this article have identified a new method that can effectively inhibit tumor formation and reduce the burden of tumors, that is, the size of the tumor, the level of cancer in the body, etc.

Original source:

Dai, M.